Overexpression of P53 MRNA in Colorectal Cancer and Its Relationship to P53 Gene Mutation
Overview
Affiliations
We analysed the frequency of p53 mRNA overexpression in a series of 109 primary colorectal carcinomas and its association with p53 gene mutation, which has been correlated with short survival. Sixty-nine of the 109 cases (63%) demonstrated p53 mRNA overexpression, without any correlation with stage or site of disease. Comparison with p53 gene mutation indicated that, besides cases in which p53 gene mutation and p53 mRNA overexpression were either both present (40 cases) or both absent (36 cases), there were also cases in which p53 mRNA was overexpressed in the absence of any mutation (29 cases) and those with a mutant gene in which the mRNA was not overexpressed (four cases). Moreover, the mutant p53 tumours exhibited an increase of p53 mRNA expression, which was significantly higher in tumours expressing the mutated allele alone than in tumours expressing both wild- and mutated-type alleles. These data (1) show that p53 mRNA overexpression is a frequent event in colorectal tumours and is not predictive of the status of the gene, i.e. whether or not a mutation is present; (2) provide further evidence that p53 protein overexpression does not only result from an increase in the half-life of mutated p53 and suggest that inactivation of the p53 function in colorectal cancers involves at least two distinct mechanisms, including p53 overexpression and/or mutation; and (3) suggest that p53 mRNA overexpression is an early event, since it is not correlated with Dukes stage.
Mammalian orthoreovirus can exit cells in extracellular vesicles.
Smith S, Krystofiak E, Ogden K PLoS Pathog. 2024; 20(1):e1011637.
PMID: 38206991 PMC: 10807757. DOI: 10.1371/journal.ppat.1011637.
Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
Qadir J, Majid S, Khan M, Rashid F, Wani M, Bhat S Pathol Oncol Res. 2021; 27:1609826.
PMID: 34924820 PMC: 8677663. DOI: 10.3389/pore.2021.1609826.
Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion.
Rizeq B, Sif S, Nasrallah G, Ouhtit A J Cell Mol Med. 2020; 24(19):11477-11488.
PMID: 32888398 PMC: 7576304. DOI: 10.1111/jcmm.15761.
Sikorska A, Flisikowska T, Stachowiak M, Kind A, Schnieke A, Flisikowski K J Appl Genet. 2018; 59(4):485-491.
PMID: 30145695 DOI: 10.1007/s13353-018-0461-6.
Gupta I, Ouhtit A, Al-Ajmi A, Rizvi S, Al-Riyami H, Al-Riyami M Endocr Connect. 2017; 7(1):65-77.
PMID: 29138235 PMC: 5744628. DOI: 10.1530/EC-17-0173.